References
- Treede R-D, Rief W, Barke A, Aziz Q, Bennett MI, Benoliel R, Cohen M, Evers S, Finnerup NB, First MB, et al. Chronic pain as a symptom or a disease: the IASP classification of chronic pain for the International Classification of Diseases (ICD-11). Pain. 2019;160(1):19–27. doi:10.1097/j.pain.0000000000001384.
- Canadian Pain Task Force. Chronic pain in Canada: laying a foundation for action. Ottawa, Canada: Health Canada; 2019 Jun.
- Schopflocher D, Taenzer P, Jovey R. The prevalence of chronic pain in Canada. Pain Res Manag. 2011;16(6):445–50. doi:10.1155/2011/876306.
- Saïdi H, Pagé MG, Boulanger A, Ware MA, Choinière M. Effectiveness of long-term opioid therapy among chronic non-cancer pain patients attending multidisciplinary pain treatment clinics: a Quebec pain registry study. Can J Pain. 2018;2(1):113–24. doi:10.1080/24740527.2018.1451252.
- Von Korff M, Saunders K, Thomas Ray G, Boudreau D, Campbell C, Merrill J, Sullivan MD, Rutter CM, Silverberg MJ, Banta-Green C, et al. De facto long-term opioid therapy for noncancer pain. Clin J Pain. 2008;24(6):521–27. doi:10.1097/AJP.0b013e318169d03b.
- Institut national d’excellence en santé et en services sociaux (INESSS). Portrait de l’usage des opioïdes chez les personnes couvertes par le régime public d’assurance médicaments du Québec. Québec (QC): INESSS; 2018.
- Chou R, Turner JA, Devine EB, Hansen RN, Sullivan SD, Blazina I, Dana T, Bougatsos C, Deyo RA. The effectiveness and risks of long-term opioid therapy for chronic pain: a systematic review for a national institutes of health pathways to prevention workshopeffectiveness and risks of long-term opioid therapy for chronic pain. Ann Intern Med. 2015;162(4):276–86. doi:10.7326/M14-2559.
- Bialas P, Maier C, Klose P, Hauser W. Efficacy and harms of long-term opioid therapy in chronic non-cancer pain: systematic review and meta-analysis of open-label extension trials with a study duration ≥ 26 weeks. Eur J Pain. 2019;24(2):265–278.
- Vowles KE, McEntee ML, Julnes PS, Frohe T, Ney JP. van der Goes DN. Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis. Pain. 2015;156(4):569–76. doi:10.1097/01.j.pain.0000460357.01998.f1.
- Jamison RN, Mao J. Opioid Analgesics. Mayo Clinic Proc. 2015;90(7):957–68. doi:10.1016/j.mayocp.2015.04.010.
- Passik SD. Issues in long-term opioid therapy: unmet needs, risks, and solutions. Mayo Clinic Proc. 2009;84(7):593–601. doi:10.1016/S0025-6196(11)60748-9.
- Butler SF, Budman SH, Fernandez KC, Houle B, Benoit C, Katz N, Jamison RN. Development and validation of the current opioid misuse measure. Pain. 2007;130(1):144–56. doi:10.1016/j.pain.2007.01.014.
- Adams LL, Gatchel RJ, Robinson RC, Polatin P, Gajraj N, Deschner M, Noe C. Development of a self-report screening instrument for assessing potential opioid medication misuse in chronic pain patients. J Pain Symptom Manage. 2004;27(5):440–59. doi:10.1016/j.jpainsymman.2003.10.009.
- Compton PA, Wu SM, Schieffer B, Pham Q, Naliboff BD. Introduction of a self-report version of the prescription drug use questionnaire and relationship to medication agreement noncompliance. J Pain Symptom Manage. 2008;36(4):383–95. doi:10.1016/j.jpainsymman.2007.11.006.
- Jamison RN, Martel MO, Edwards RR, Qian J, Sheehan KA, Ross EL. Validation of a brief opioid compliance checklist for patients with chronic pain. J Pain. 2014;15(11):1092–101. doi:10.1016/j.jpain.2014.07.007.
- Jamison RN, Martel MO, Huang CC, Jurcik D, Edwards RR. Efficacy of the opioid compliance checklist to monitor chronic pain patients receiving opioid therapy in primary care. J Pain. 2016;17(4):414–23. doi:10.1016/j.jpain.2015.12.004.
- Statistics Canada. Le français, l’anglais et les minorités de langue officielle au Canada. 2017. https://www12.statcan.gc.ca/census-recensement/2016/as-sa/98-200-x/2016011/98-200-x2016011-fra.cfm.
- Lawrence R, Mogford D, Colvin L. Systematic review to determine which validated measurement tools can be used to assess risk of problematic analgesic use in patients with chronic pain. Br J Anaesth. 2017;119(6):1092–109. doi:10.1093/bja/aex316.
- Parikh R, Mathai A, Parikh S, Chandra Sekhar G, Thomas R. Understanding and using sensitivity, specificity and predictive values. Indian J Ophthalmol. 2008;56(1):45–50. doi:10.4103/0301-4738.37595.
- Scottish Intercollegiate Guidelines Network. Critical appraisal: notes and checklists. Edinburgh, Scotland: Scottish Intercollegiate Guidelines Network; 2007.
- Beaton DE, Bombardier C, Guillemin F, Ferraz MB. Guidelines for the process of cross-cultural adaptation of self-report measures. Spine. 2000;25(24):3186–91. doi:10.1097/00007632-200012150-00014.
- Government of Canada. Cannabis Act. In. S.C. 2018, c. 16 2019.
- Rieder TN. There’s never just one side to the story: why America must stop swinging the opioid pendulum. Narrat Inq Bioeth. 2018;8(3):225–31. doi:10.1353/nib.2018.0071.
- Gruss I, Firemark A, Mayhew M, McMullen CK, DeBar LL. Taking opioids in times of crisis: institutional oversight, chronic pain and suffering in an integrated healthcare delivery system in the U.S. Int J Drug Policy. 2019;74:62–68. doi:10.1016/j.drugpo.2019.08.009.